Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LC16m8 mpox vaccine effectiveness and safety study in the DRC
PACTR202510844951278Phase 4Recruiting
- Sponsor
- Institut National de la Recherche Biomedicale
- Start
- Sep 2025
- Countries
- 1
01
Overview
Phase 4, open-label trial in mpox (3 arms), sponsored by Institut National de la Recherche Biomedicale. Primary endpoint: Vaccine effectiveness based on complete vaccination status among RT-PCR positive versus RT-PCR negative symptomatic participants. Started Sep 2025; status: recruiting.
02
Conditions
mpox
Beyond the preview
Go deeper on PACTR202510844951278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202510844951278.